Epstein - Barr Virus Capsid Antigen (EBV-VCA) IgM antibodies among HIV infected individuals in Jos, Nigeria.
Author(s) -
Joseph Anejo-Okopi,
Ocheme Julius Okojokwu,
Nenkimwa Adamu,
Juliet Ogbonna,
Joshua Adetunji,
Gabriel Ikwulono
Publication year - 2019
Publication title -
trends journal of sciences research
Language(s) - English
Resource type - Journals
eISSN - 2377-8091
pISSN - 2377-8083
DOI - 10.31586/microbiology.0403.02
Subject(s) - capsid , virology , antibody , human immunodeficiency virus (hiv) , virus , antigen , epstein–barr virus , biology , immunology
Human immunodeficiency virus (HIV) infection is associated with an increased risk for Viral infections such as Epstein-Barr virus (EBV)infections also known as Human Herpes Virus Type 4 (HHV-4) and their related diseases which frequently cause malignancy related diseases resulting to poor treatment and health outcomes. In this study, we determined the seroprevalence of EBV VCA IgM antibodies among HIV patients attending Plateau Specialist Hospital, Jos, Nigeria and to evaluate their association with age, sex as well as other demographic factors. A total of 92 HIV positive patients were enrolled and serum samples were screened for antibodies using the ELISA kit. The prevalence of EBV VCA IgM was 6/92(6.53%), and mean age of 37.48 ±1.01 years. This study has contributed to baseline data, and suggest the need for larger studies and importance of screening and treatment of EBV among HIV patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom